References
- National Comprehensive Cancer N. B-Cell Lymphomas (Version 3). 2021. https://www.nccn.org/professionals/physician_gls/pdf/b-cell_blocks.pdf.
- Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011; 2011/07/01/100(1):86–92.
- Manus MPM, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14(4):1282–1290.
- Vargo JA, Gill BS, Balasubramani GK, et al. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121(18):3325–3334.
- Pugh TJ, Ballonoff A, Newman F, et al. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation. Cancer. 2010;116(16):3843–3851.
- Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202–1208.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
- Garrido MM, Kelley AS, Paris J, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014;49(5):1701–1720.
- StataCorp. 2015. Stata statistical software: release 14.,. College Station (TX): stataCorp LP.
- MacManus M, Fisher R, Roos D, et al. Randomized trial of systemic therapy after Involved-Field radiotherapy in patients with Early-Stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36(29):2918–2925.
- Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma []. Cancer. 2010; 2010/08/15116(16):3797–3806.
- Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21(13):2474–2480.
- Hoskin P, Popova B, Schofield O, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22(3):332–340.
- Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22(8):1454–1459.
- Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the national LymphoCare study. J Clin Oncol. 2012;30(27):3368–3375.
- Brady JL, Binkley MS, Hajj C, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133(3):237–245.
- Lo AC, Campbell BA, Pickles T, et al. Long-Term outcomes for patients with limited stage follicular lymphoma: an update of a population-based study. International Journal of Radiation Oncology, Biology, Physics. 2019;105(1):S33–S34.
- Sha F, Okwali M, Alperovich A, et al. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer J. 2022;12(2):29.
- Spry NA, Lamb DS, Vaughan Hudson G, et al. Localized grade I non-Hodgkin’s lymphoma: results of treatment with radiotherapy alone in 88 patients. Clinical Oncology. 1989;1(1):33–38. 1989/09/01/
- Mac Manus MP, Hoppe RT. Overview of treatment of localized low-grade lymphomas. Hematology/Oncology Clinics of North America. 1997; 1997/10/01/11(5):901–918.
- Yang JC, Elkin EB, Parikh R, et al. Cost-effectiveness analysis of first-line treatments for early-stage, low-grade follicular lymphoma. J Clin Oncol. 2017;35(15_suppl):6619–6619. 2017/05/20
- Tepasse P-R, Hafezi W, Lutz M, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 2020;190(2):185–188.
- Dougados M. Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic. Lancet Rheumatol. 2021; 2021/06/01/3(6):e395–e396.
- Lee CY, Shah MK, Hoyos D, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022;12(1):62–73.
- Shree T, Shankar V, Lohmeyer JJK, et al. CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity. Blood Cancer Discov. 2022;3(2):95–102.
- Cheson BD, Fisher RI, Barrington SF, United Kingdom National Cancer Research Institute, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
- Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of french and US cohorts. J Clin Oncol. 2019;37(2):144–152.